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A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for 
people with dementia: examining the influence of cognitive ability and living 
arrangements.  
 
Abstract  
Objectives: Identify if cost-effectiveness of Maintenance Cognitive Simulation Therapy 
(MCST) differs by type of living arrangement and cognitive ability of the person with dementia.  
Findings are used to perform a value of information analysis to inform decisions about future 
research on the effectiveness and cost-effectiveness of MCST in people with these 
characteristics. 
Methods: Incremental cost-effectiveness analysis applying seemingly unrelated regressions 
using data from a multicentre RCT of MCST versus treatment as usual in a population which 
had already received 7 weeks of CST for dementia (ISRCTN: 26286067).  The findings from 
the cost-effectiveness analysis are used to inform a value of information analysis.   
Results:  The results are dependent upon how quality adjusted life years (QALYs) are 
measured but suggest that MCST might be cost-effective compared to standard treatment for 
those who live alone and for individuals with higher levels of cognitive functioning.  If a further 
RCT was to be conducted evaluating the cost-effectiveness of MCST for those with higher 
cognitive functioning and those who lived alone, value of information analysis suggests a total 
sample of 48 complete cases for both sub-groups would be required for a two-arm trial.  The 
expected net gain of conducting future research for these two population sub-groups is £920 
million.   
Conclusion: Preliminary results suggest that MCST may be most cost-efficient for people with 
dementia who live alone and/or who have higher cognition. Future research in this area is 
needed.  
Key Words: Maintenance Cognitive Simulation Therapy; Cognitive Functioning; Residency; 
Cost-effectiveness; Expected Value of Sample Information 
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Introduction  
Approximately 46.8 million people worldwide are living with dementia. In 2015, it was 
projected that dementia cost the worldwide economy $818 billion USD (Prince et al. 2015). 
Globally the number of people living with dementia is predicted to increase; yet there is still 
much to do to improve both the quality of their lives and the quality of care they receive (Prince 
et al. 2013). There is a growing evidence base supporting non-pharmacological interventions, 
with systematic reviews helping to summarise the evidence (Knapp et al. 2013; Prince et al. 
2011); however for some interventions, the research to date is limited to small, poor quality 
studies (Olarazan et al 2004). Cognitive Stimulation Therapy (CST) is a 7-14 weeks, group-
based, non-drug intervention delivered by a trained group facilitator, in which individuals 
participate in a range of cognitive and social exercises.  High quality trials have shown that 
CST delivers significant patient benefits (cognitive function, communication, quality of life) 
(Orrell et al. 2014; Knapp et al. 2006;Spector et al. 2003) whilst systematic reviews have 
confirmed its cost-effectiveness (Knapp et al. 2012; Prince et al. 2011).  It is one of a small 
number of non-drug interventions to be recommended as part of routine care in international 
guidance (Prince et al. 2011; NICE 2013).   
Maintenance Cognitive Simulation Therapy (MCST) is an extension of CST delivered over 16-
24 weeks. Results from a multicentre, randomised controlled trial comparing MCST with a 
single CST course (ISRCTN: 26286067) (Orrell et al. 2014) showed that MCST improved 
cognition for patients taking acetylcholinesterase inhibitor medication (ACHEIs) but the 
primary economic evaluation reported mixed results (D’Amico et al. 2015).  Compared to 
current treatment, the likelihood of MCST being cost-effective was dependent upon how 
quality of life was measured. Questions remain as to whether certain subgroups of people with 
dementia might benefit more than others from MCST; a more targeted use of MCST might be 
a more efficient- use of resources.  
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The aim of this paper was to determine whether MCST was more cost-effective for specific 
sub-groups of people living with dementia based on their level of cognition and living 
arrangements- either in the community or in a care home. The analysis is best considered 
exploratory and hypothesis-generating; we use value of information (VOI) analysis (Willian 
and Pinto 2005) as a means to reduce uncertainty around these estimates to help inform future 
research decisions.   
Methods 
Data: 
The data utilised in this study were collected for the within-trial economic analysis (D’Amico 
et al. 2015). Details of the trial population are reported elsewhere (Orrell et al 2014) The 
analysis employed a societal perspective i.e. that is both  costs and benefits borne by the health 
sector are considered  alongside those of the individual and their carers’.  The cost and outcome 
data is the same as that used in the primary economic evaluation (D’Amico et al 2015) and the 
assumptions underlying the generation of the cost and benefit variables are outlined there.   
All analyses was divided by five subgroups which were defined as: a person with dementia 
who lives in the community either i) with family/friends ii) on their own or iii) in a care home 
and whether their cognition, as measured by ADAS-Cog (Alzheimer’s Disease Assessment 
Scale-Cognition) subscale was in the iv) upper or v) lower 50% score range, where lower scores 
reflect better cognition.  For the sample the 50% cut-off was a score of 39.   
Sub-group categories are not mutually exclusive.  If individuals are in two sub-groups then 
their data will be used in the analysis for both sub-groups of which they are members.  The 
sample size is too small to do any additional analysis on participants who are classified as being 
part of more than one sub-group (e.g. higher cognitive functioning/living alone)  (n=29).   
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Table 1 reports the numbers of study participants in either treatment arm falling into each of 
the specified sub-groups. The numbers in each residential sub-group are small re-emphasising 
that results should be considered exploratory.   
Outcome Variables 
The costs used in the analysis relate to the NHS and local authorities, patients, and families (i.e. 
carers).  Table 2 shows a breakdown of the different costs from a societal perspective.  the costs 
of unpaid carer inputs (which are used as the cost measures in the main analysis) from a societal 
perspective for each sub-group of interest.  The largest societal costs were reported for those 
living in the community with a friend or family member, followed by those with lower 
cognitive functioning.  The standard deviations reported in Table 2 illustrate the highly skewed 
nature of the data showing that a number of participants had very high costs.   
Effectiveness measures used in the analysis are: 
EQ-5D 3L (self-reported) and EQ-5D 3L proxy (completed by family carers or care centre 
workers) - a generic health related quality of life measure where higher scores indicate a better 
quality of life EuroQol Group 1990).  
DEMQOL (self-reported) and DEMQOL proxy (completed by family carers or care centre 
workers) - a  dementia-specific quality of life score where higher scores indicate better quality 
of life (Smith et al. 2007;Rowen et al. 2012).   
Effectiveness measures collected These measures were collected prior to receiving any 
interventions, after the seven weeks of the initial CST programme (baseline), three months 
after the beginning of the MCST groups, and six months after the start of the MCST groups 
(Orrell et al 2014) are used to estimate QALYs using the area under the curve approach 
(Whitehead and Ali 2010).  
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Table 3 presents the quality of life scores at each of the study measurement points.  These are 
reported for each treatment and sub- group.  
Incremental Cost Effectiveness Analysis:    
Data collected on costs and effects of the intervention were combined to obtain an incremental 
cost-effectiveness ratio (ICER) for each sub-group. ICERs were estimated using a seemingly 
unrelated regression (SUR) approach.  This approach assumes that there were correlated 
unobserved factors associated with both costs and benefits (Willan et al. 2004). In this analysis, 
differences in mean costs and effects are adjusted for baseline characteristics of the study group, 
such as marital status, gender, age, and baseline cognitive functioning to correct for subtle 
imbalances between the treatment and intervention groups.    
The analysis calculates the mean difference in costs between the intervention and control 
groups divided by the difference in effect between the intervention and control groups for each 
sub-group.  This gives us the cost per additional unit of effectiveness (e.g. a QALY gained) for 
MCST relative to standard practice. 
To represent the statistical imprecision surrounding estimates of costs and cost-effectiveness 
the results are presented as plots of costs and effects and cost-effectiveness acceptability curves 
(CEACs).  CEACs show the probability that an intervention would be considered cost-effective 
at different threshold values for society’s willingness to pay for a one unit increase in quality 
of life as measured by EQ-5D and DEMQOL.  If society is willing to pay this upper value then 
they will be willing to pay a lower value.   
To produce plots of costs and effects and CEACs the estimates of mean costs and effects for 
each sub-group were bootstrapped 1000 times.  These bootstrapped estimates were then plotted 
and used to estimate the Net Benefit statistic, which represents society’s willingness to pay for 
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a unit of effectiveness as measured by an improvement in health related quality of life. In the 
UK, this value for a QALY is typically set at £20,000 (NICE 2013).  
Value of information 
Next, we performed Expected Value of Sample Information (EVSI) analysis for any of the sub-
groups identified where MCST may be cost-effective.  EVSI is used to compare the value of 
information from a future research trial with the total costs (TC) of obtaining this information 
to calculate the expected net gain (ENG) from conducting further research (Willan and Pinto 
2005). To estimate the EVSI, the number of patients to benefit from a further trial is multiplied 
by the expected opportunity loss per patient of this additional research (as the intervention is 
not being implemented).   Formally this is shown using the formula below: 
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Where:  
b0 and v0 = incremental net benefit and variance at time 0 (before trial) 
b1 and v1= incremental net benefit and variance at time 1 (once additional information becomes 
available) 
Eb̂  = the estimate of incremental net benefit derived from the trial data 
CA = the cost of adopting the new intervention into clinical practice  
h  = the time horizon (or the useful life expectancy of the intervention)-10 years in this case 
k  = severity of dementia to which the intervention should be applied  
FC / VC= the fixed and variable cost components of running a new trial. 
a  = the annual accrual rate into the trial 
N(n)= number of patients to benefit from the new information-number of new annual diagnosis 
of cognitive impairment in the UK (225,000 new individuals diagnosed with 
dementia is the figure we use in the analysis). 
 
If the analysis shows that EVSI<£0, then current information is adequate for decision-making, 
and no further research is needed.  If EVSI has a positive value this suggests there is value to 
be gained from future research. A positive ENG means the value of acquiring additional 
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information from running a future trial on the population group of interest exceeds its cost and 
it worthwhile to fund this additional research.   
As a comparison to optimal sample size calculations from EVSI a standard sample size 
calculation was estimated using the standard deviations from the control and treatment groups.  
Recent guidance suggests that several approaches should be considered to determine sample 
size (Cook et al. 2014). 
Results 
Incremental Cost-Effectiveness Analysis: 
Table 4 presents the incremental costs, effects and incremental cost per unit of effect for each 
treatment comparison and each sub-group from a societal perspective.  Because we need 
complete data on both costs and effects and baseline characteristics the sample sizes do not 
directly correspond to the simpler analyses presented in Tables 1-3.   
Table 5 shows that for the majority of the sub-groups current care either dominates or MCST 
is associated with a very high incremental cost per unit of increase in HRQoL.  The exceptions 
are where we consider comparisons for those who live alone, where treatment on average 
dominates or where the incremental cost per unit of effect gained is modest.  Other exceptions 
are for the comparisons for those within a care home using the Proxy DEMQOL and those in 
the upper 50% of scores at baseline using the ADAS-COG using the QoL-AD and Proxy 
DEMQOL. 
Because of the small sample sizes, the results in Table 5 are associated with considerable 
uncertainty.  Cost-effectiveness acceptability curves are therefore presented in tabular form 
(columns showing probability cost-effectiveness given society’s willingness to pay for a 
QALY estimated using EQ-5D-3L for each sub-group.)  In addition, Figure 1 shows the cost-
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effectiveness acceptability curves in a graphical format.  Only for those that live alone is there 
a probability that treatment is likely to be cost-effective. 
EVSI: 
From the cost-effectiveness analysis two sub-groups showed the most promising results in 
terms of potential cost-effectiveness: patients with higher cognitive functioning measured 
using the ADAS-Cog and patients that live alone.  Given the considerable imprecision around 
the estimates of cost-effectiveness, because of the small sample sizes for each sub-group, it is 
reasonable to question how worthwhile it would be to conduct further research to investigate 
whether treatment could be cost-effective for these sub-groups.   Figure 1 shows the EVSI and 
ENG for each sample size.  The optimal sample size is where both ENG and EVSI are at their 
highest value.  The VOI analysis showed that there was added value to be gained from 
additional research. The ENG of this additional research is £920m which is greater than the 
cost of £41m  (financial cost of conducting the trial plus the opportunity cost of not conducting 
this additional research). We would need complete case information on 17 patients in each arm 
or 34 complete cases to maximise ENG.  Allowing for an attrition rate of 40% means that a 
sample size of 48 would be required.  In the trial an attrition rate of 13% was observed (Orrell 
et al. 2014).  
Sample Size Calculation:  
Standard statistical tests were employed to calculate the sample size that would be required if 
a trial on MCST was run on the two sub-groups.  The sample size required to detect a 
statistically significant difference at p<0.05 of one standard deviation in the outcome measure 
would be n=59 for each arm or n=118 in total.    
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If it was decided that a future trial were to be conducted, the two sample size calculations could 
be compared and contrasted to determine the optimal sample size for a future trial. 
 
Discussion 
Our results identify two sub-groups where MCST might potentially be cost-effective: 1) people 
with dementia with higher cognitive functioning as measured by the ASAS-Cog and 2) people 
with dementia who live alone.  Because of the small sample sizes used in the analysis and the 
fact that the trial where the data comes from was not powered to detect changes by the sub-
groups used in the analysis these results should be interpreted with caution.  Bootstrapping 
removes some of this uncertainty but it is possible that our sample may not be representative 
of the general population in these sub-groups.  EVSI showed that a more modest sample size 
of 34 complete cases would be required to confirm that standard treatment is the most cost-
effective option compared with MCST for these two sub-groups.  This compares with 
conventional statistical approaches which suggest that to identify a difference of 5% between 
groups a sample of 118 complete cases would be needed.  From an economic perspective the 
sample required for an internally valid RCT is smaller when using the value of information 
approach than when using a conventional statistical approach.  In reality a larger sample size 
may be needed to provide reassurance about the external validity of the trial findings than 
predicted by the value of information analysis.  A larger sample size would also give protection 
from other features not currently considered e.g. clustering of outcomes. 
Nevertheless, the expected net gain (ENG) to the UK NHS of this additional research is £920m; 
this represents a considerable value and reflects the rapidly ageing populations and predicted 
future costs of dementia care (Prince et al 2013; Prince et al. 2015) as well as the need to 
identify more cost effective service provision (Knapp et al. 2013) in a time of financial austerity.   
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Approximately one-third of people with dementia live alone (Mirando-Castillo et al. 2010). 
People with dementia who live alone may be one of the groups to benefit most from CST; this 
group often present greater challenges for care professionals.  Those living alone are have a 
higher risk of admission to care homes than those who live with other family members.  The 
costs of being in a care home will be higher than those of community care.   If, as our data 
suggests, MCST may be cost-effective in terms of benefits measured as QALYS compared to 
the cost of the intervention such therapy may help facilitate independent living for longer in a 
group who are at higher risk of being admitted to care homes or hospital (Knapp et al. 2016; 
Luppa et al. 2010;  Yaffe et al. 2002; Herbert et al. 2001).  For those with higher cognitive 
functioning, MCST may reduce the rate of cognitive decline, keeping these individuals 
independent for longer requiring less high cost care such as day care centres etc.    
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Table 1: Samples in each sub-group 
Sub-group  Treatment  Control 
Living 
arrangements 
Living alone 
n=46  
Baseline: 23 
1-3 mths: 23 
4-6 mths: 22 
Baseline: 23 
1-3 mths: 23 
4-6 mths: 23 
 
 Lives with 
someone 
n=63 
Baseline: 37 
1-3 mths: 37 
4-6 mths: 35 
Baseline: 26 
1-3 mths: 26 
4-6 mths: 22 
 Care home 
n=92 
Baseline: 44 
1-3 mths: 44 
4-6 mths: 40 
Baseline: 48 
1-3 mths: 48 
4-6 mths: 42 
ADAS-Cog  ADAS-Cog 
(upper 50%) 
n=104 
Baseline: 57 
1-3 mths: 62 
4-6 mths: 58 
Baseline:47 
1-3 mths: 47 
4-6 mths: 43 
 ADAS-Cog 
(lower 50%) 
n=104 
Baseline: 52 
1-3 mths: 52 
4-6 mths: 52 
Baseline: 62 
1-3 mths: 57 
4-6 mths: 50 
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Table 2: Cost of unpaid carer inputs (0-6 months) from a societal perspective by sub-group and allocation group using the opportunity cost 
assumption 
 Control Treatment 
Cost of 
intervention 
Care 
Home  
Lives 
alone 
Lives with 
someone 
ADAS-
Cog 
(lower 
50%) 
ADAS-
Cog 
(upper 
50%) 
Care 
Home  
Lives 
alone 
Lives with 
someone 
ADAS-
Cog 
(lower 
50%) 
ADAS-
Cog 
(upper 
50%) 
 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Total Health and 
Social care costs 
17381 
(4200) 
5900 
(4874) 
3157 
(3169)  
13684 
(6929) 
8831 
(8380) 
18520 
(3701) 
5973 
(3933) 
4250 
(2848) 
14535 
(7367)  
8633 
(7306) 
Unpaid carer costs 104 (460) 
3255 
(4315) 
11868 
(7459) 
2714 
(6130) 
4960 
(6600) 
115 (509) 
3080 
(3000) 
14603 
(8064) 
4140 
(7898) 
6633 
(8140) 
Total societal costs 
17485 
(3947) 
9155 
(5100) 
15026 
(7250) 
16398 
(5614) 
13791 
(6802) 
18635 
(3627) 
9053 
(3973) 
18853 
(7639) 
18675 
(5093) 
15266 
(7575) 
n 42 22 23 50 43 40 22 35 48 58 
a ADAS-Cog measured at baseline. CST intervention costs measured pre-baseline for 7 weeks of CST for both treatment and control. 
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Table 3: Quality of Life Measures By Time Point, Allocation Group and Sub Category 
Tool Control     Treatment     
 Care Home  Lives alone 
Lives with 
someone 
ADAS-Cog 
(lower 50%) 
ADAS-Cog 
(upper 50%) 
Care Home  Lives alone 
Lives with 
someone 
ADAS-Cog 
(lower 50%) 
ADAS-Cog 
(upper 50%) 
Baseline 
QoL-AD 
36.5 (34.8-
38.3) 
37.9 (35.9-
40.0) 
35.6 (33.1-
38.2) 
35.4(33.8-
36.9) 
38.1 (36.6-
39.6) 
35.1 (33.5-
36.8) 
36.7 (35.5-
37.8) 
37.3 (35.7-
39.0) 
36.3 (35.0-
37.5) 
36.1 (34.8-
37.3) 
DEMQOL 
96.2 (93.8-
98.5)) 
95.6 (90.8-
100.3) 
93.6 (86.8-
100.4) 
94.6 (91.3-
97.9) 
96.1 (92.8-
99.3) 
93.8 (90-
97.7) 
95.7(91.4-
100) 
95.4 (91.9-
98.9) 
96.7(94-
99.2) 
93.3 (90.2-
96.4) 
Proxy 
DEMQOL 
102.1 (100.0-
105.8) 
104.5 (99.4-
110.0) 
100.0 (94.7-
104.9) 
101.6 (98.5-
104.6) 
103.4 
(100.0-
106.8) 
106.1(102.7-
109.5) 
99.3 (93.5-
105.1) 
98.7 (93.3-
104.2) 
102.3 (98.5-
106.1) 
102.4 (98.9-
105.9) 
EQ-5D 0.8 (0.7-0.8) 0.9 (0.8-1.0) 0.8 (0.7-0.9) 0.8 (0.7-0.9) 0.8 (0.7-0.9) 0.8 (0.7-0.8) 0.8 (0.7-0.9) 0.8 (0.7-0.9) 0.8 (0.7-0.9) 0.8 (0.7-0.8) 
 Proxy EQ-
5D 
0.7 (0.6-0.7) 0.8 (0.7-0.9) 0.7 (0.6-0.8) 0.7 (0.6-0.7) 0.7 (0.6-0.8) 0.7 (0.6-0.8) 0.7 (0.6-0.8) 0.6 (0.5-0.7) 0.7 (0.6-0.7) 0.7 (0.6-0.8) 
3 MONTHS 
QoL-AD 
35.3 (33.5-
37.1) 
39.2 (37.6-
40.9) 
36.0 (33.7-
38.2) 
35.9 (34.2-
37.5) 
36.9 (35.5-
38.4) 
35.8 (34.1-
37.5) 
35.8 (34.1-
37.4) 
37.5 (35.7-
39.4) 
36.5 (35.0-
38.1) 
36.2 (34.9-
37.5) 
DEMQOL 
95.9 (92.5-
99.3) 
95.6 (91.6-
100.3) 
93.8 (89.4-
98.2) 
95.7 (92.8-
98.7) 
94.4 (91.3-
97.6) 
95.1 (91.4 -
98.8) 
 95.1(90.2-
100) 
93.3 (89-
97.6) 
96.6 (93.7-
99.4) 
92 (88.7-
95.4) 
Proxy 
DEMQOL 
103.8 (100.8-
106.8) 
100.0 (96.1-
103.8) 
97.5 (93.5-
101.6) 
100.1 (97.0-
103.3) 
100.1 (97.3-
102.9) 
103.8 
(100.8-
106.8) 
100.0 (96.1-
103.8) 
97.5 (93.5-
101.6) 
100.1 (97.0-
103.3) 
100.1 (97.3-
102.9) 
 EQ-5D 0.8 (0.7-0.8) 0.9 (0.9-1.0) 0.8 (0.7-0.9) 0.8 (0.7-0.9) 0.8 (0.7-0.9) 0.8 (0.7-0.8) 0.8 (0.7-0.9) 0.8 (0.7-0.9) 0.8 (0.7-0.9) 0.8 (0.7-0.8) 
 Proxy EQ-
5D 
0.5 (0.5-0.6) 0.7 (0.6-0.8) 0.6 (0.5-0.7) 0.5 (0.5-0.6) 0.6 (0.5-0.7) 0.6 (0.6-0.7) 0.7 (0.6-0.8) 0.6 (0.5-0.7) 0.6 (0.5-0.7) 0.7 (0.6-0.7) 
6 MONTHS 
QoL-AD 
35.6 (33.5-
37.6) 
38.2 (36.4-
40.1) 
34.9 (32.3-
37.5) 
36.0 (34.0-
37.8) 
35.8 (34.2-
37.4) 
36.0 (34.0-
37.9) 
36.6 (34.5-
38.8) 
38.6 (36.8-
40.4) 
37.1 (35.4-
38.8) 
37.1 (35.7-
38.5) 
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DEMQOL 
95.3 (91.7-
99) 
96.4 (90.7-
102.1) 
93 (86.9-99) 
96 (92.1-
100) 
93.8 (90.3-
97.4) 
96.4 (93.2-
99.7) 
95.8 (90.5-
101) 
93 (88-98) 
97 (94.1- 
100) 
93.2 (90-
96.5) 
Proxy 
DEMQOL 
105.3 (102.0-
108.6) 
97.5 (91.1-
103.9) 
97.1 (89.4-
104.7) 
100.0-96.0-
103.7) 
103.0 (98.8-
107.2) 
106.5 
(103.1-
110.0) 
97.6 (92.8-
102.4) 
97.5 (93.3-
101.7) 
102.0 (98.8-
105.1) 
100.1 (96.6-
103.6) 
EQ-5D 0.8 (0.7-08) 0.9 (0.8-0.9) 0.7 (0.5-0.8) 0.8 (0.7-0.8) 0.8 (0.7-0.8) 0.7 (0.6-0.8) 0.8 (0.8-0.9) 0.8 (0.7-0.9) 0.8 (0.7-0.9) 0.8 (0.7-0.8) 
 Proxy EQ-
5D 
0.6 (0.5-0.7) 0.7 (0.6-0.8) 0.6 (0.4-0.7) 0.5 (0.4-0.6) 0.7 (0.6-0.8) 0.7 (0.6-0.8) 0.6 (0.4-0.7) 0.6 (0.5-0.7) 0.5 (0.5-0.6) 0.7 (0.6-0.8) 
aConfidence Intervals are in parenthesis. 
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Table 4: Incremental cost-effectiveness ratios, from a societal perspective, over 1-6 month by sub-categories 
 Care Home Lives Alone Lives with someone ADAS-Cog (lower 
50%) 
ADAS-Cog (upper 
50%) 
1-6 
Months 
Incr 
Cost 
Incr 
Effect 
ICER Incr 
Cost 
Incr 
Effect 
ICER Incrl 
Cost 
Incr 
Effect 
ICER 
(£ 
Incr 
Cost 
Incr 
Effect 
ICE
R 
Incr 
Cost 
Incr 
Effect 
ICER 
 Mean 
[95% 
CI] 
Mean 
[95% 
CI] 
 Mean 
[95% 
CI] 
Mean 
[95% 
CI] 
 Mean 
[95% 
CI] 
Mean 
[95% 
CI] 
 Mean 
[95% 
CI] 
Mean 
[95% 
CI] 
 Mean 
[95% 
CI] 
Mean 
[95% 
CI] 
 
QALY 
(EQ-
5D) 
909 
[14, 
1804] 
-0.01 [-
0.07, 
0.06] 
Con 
Dom 
-194 [-
5138, 
4751 
0.07 [-
0.13, 
0.27] 
1082
8 
2260 
[-
2325, 
6844] 
0.01 [-
0.08, 
0.10] 
23164
2 
1215 
[-328, 
2758] 
0.00 [-
0.05, 
0.05] 
7867
13 
477 [-
2390, 
3344] 
0.00 [-
0.05, 
0.05] 
2362
20 
QALY 
(Proxy 
EQ-5D) 
904 [5, 
1803] 
-0.03 [-
0.13, 
0.07] 
Con 
Dom 
-149 [-
5109, 
4811] 
0.10 [-
0.09, 
0.30] 
7419 2246 
[-
2321, 
6813] 
0.04 [-
0.08, 
0.15] 
61175 1216 
[-324, 
2755] 
-0.02 [-
0.06, 
0.02] 
Con 
Dom 
472 [-
2413, 
3357] 
0.03 [-
0.03, 
0.09] 
1445
7 
QALY 
(DEM
QOL) 
960 [-
140, 
2060] 
-0.002 
[-0.07, 
0.07] 
Con 
Dom 
-2472 
[-
13163 
82193] 
0.08 [-
0.29, 
0.44] 
-7955 2771 
[-
3163, 
8704] 
0.01 [-
0.07, 
0.09] 
30218
4 
1567 
[-310, 
3444] 
-0.01 [-
0.04, 
0.02] 
Con 
Dom 
939 [-
2299, 
4177] 
0.02 [-
0.004, 
0.05] 
4145
8 
QALY 
(Proxy 
DEMQ
OL) 
922 [-
11, 
1855] 
0.01 [-
0.02, 
0.04] 
12988
6 
-195 [-
5204, 
4815] 
-0.02 
[-0.10, 
0.07] 
1168
3 
2523 
[-
2204, 
7251] 
0.002 
[-0.06, 
0.06] 
15447
65 
1201 
[-355, 
2757] 
0.004 
[-0.01, 
0.02] 
2894
26 
617 [-
2342, 
3577] 
0.02 [-
0.01, 
0.05] 
2588
9 
aCost in 2010/11 UK pounds; 
b all CIs based upon bootstrapping mean differences with 1000 replications 
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Table 5: Incremental cost per QALY (estimated using self-reported EQ-5D) from a societal perspective by sub-group 
Sub 
group 
Intervent
ion 
Increme
ntal cost 
(£) 
Increme
ntal 
QALYs 
Increme
ntal cost 
per 
QALY 
Probability cost-effective given society's 
willingness to pay for a QALY 
£0 
£20,
000 
£30,
000 
£50,
000 
Upper 
cogniti
ve  
Control     78
% 73% 70% 65% 
Treatme
nt 
477 0.00 £236,22
0 
22
% 27% 30% 35% 
Lower 
cogniti
ve 
Control     82
% 76% 72% 67% 
Treatme
nt 
1215 0.00 £786,71
3 
18
% 24% 28% 33% 
Lives 
with 
someo
ne 
Control     94
% 77% 70% 59% 
Treatme
nt 
2260 0.01 £231,64
2 6% 23% 31% 41% 
Lives 
alone 
Control     63
% 45% 41% 37% 
Treatme
nt 
-194 0.07 -2667 37
% 55% 59% 63% 
Care 
home 
Control     10
0% 82% 69% 55% 
Treatme
nt 
909 -0.01 Con 
Dom 0% 18% 31% 45% 
aTx Dom = treatment dominant; Con Dom = control dominant 
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Table 6: Expected Value of Sampling Information Results 
n*  17 
EVSI  £ 
962,178,716 
 
Financial Cost  £375,004 
Opportunity Cost  £ 
40,858,057 
 
Total Cost  £ 
41,233,061 
 
ENG  £  
920,945,655 
 
aComplete cases in a single arm of a study 
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Figure 1: Cost Effectiveness Acceptability Curves for the 5 Sub-groups 
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Figure 2: Expected Value of Sample Information 
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